CA
REGN icon

Callahan Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Callahan Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$714K Hold
924
– – 0.06% 126
2025
Q4 		$713K Sell
924
-7
-0.8% -$4.75K 0.06% 128
2025
Q3 		$524K Sell
931
-4
-0.4% -$2.26K 0.04% 123
2025
Q2 		$491K Hold
935
– – 0.04% 125
2025
Q1 		$593K Buy
935
+69
+8% +$47.5K 0.06% 124
2024
Q4 		$617K Buy
+866
New +$727K 0.06% 124

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Callahan Advisors's REGN Position: Q1 2026 in Review

Callahan Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 924 shares worth $714K. The position accounts for 0.06% of the portfolio, ranked #126.

Callahan Advisors first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Callahan Advisors held 924 shares of Regeneron Pharmaceuticals worth $714K as of Q1 2026.
  • Callahan Advisors left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.06% of Callahan Advisors's portfolio in Q1 2026, its #126 holding.
  • Callahan Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Callahan Advisors's 13F filing for Q1 2026, filed 12 May 2026.